3qo9
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
==About this Structure== | ==About this Structure== | ||
| - | [[3qo9]] is a 2 chain structure | + | [[3qo9]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_type_1_bh10 Human immunodeficiency virus type 1 bh10]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QO9 OCA]. |
==See Also== | ==See Also== | ||
Revision as of 10:34, 20 October 2012
Contents |
Crystal structure of HIV-1 Reverse Transcriptase (RT) in complex with TSAO-T, a non-nucleoside RT inhibitor (NNRTI)
Template:ABSTRACT PUBMED 21446702
About this Structure
3qo9 is a 2 chain structure with sequence from Human immunodeficiency virus type 1 bh10. Full crystallographic information is available from OCA.
See Also
Reference
- Das K, Bauman JD, Rim AS, Dharia C, Clark AD, Camarasa MJ, Balzarini J, Arnold E. Crystal Structure of tert-Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket. J Med Chem. 2011 Apr 28;54(8):2727-2737. Epub 2011 Mar 29. PMID:21446702 doi:10.1021/jm101536x
- Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1466-71. Epub 2008 Jan 29. PMID:18230722
- Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004 May 6;47(10):2550-60. PMID:15115397 doi:http://dx.doi.org/10.1021/jm030558s
